Transient receptor potential melastatin 2: A novel target for treatment of gout

Expert Opinion on Therapeutic Targets

Volumn 17, Issue 11, 2013, Pages 1243-1247

  Zhong, Zhenyu ^a,b   Zhai, Yougang ^a   Qiao, Liang ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gout; Inflammation; NOD like receptor pyrin domain containing 3 inflammasome; Transient receptor potential melastatin 2

Indexed keywords

ALLOPURINOL; CALCIUM; CANAKINUMAB; CATHEPSIN B; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; DNA; INFLAMMASOME; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT PROTEIN; RECOMBINANT TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; RILONACEPT; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; UNCLASSIFIED DRUG; URATE;

CALCIUM TRANSPORT; CELL PROLIFERATION; CELL SURVIVAL; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOSOL; DIARRHEA; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GLUCOSE BLOOD LEVEL; GOUT; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY DYSFUNCTION; MACROPHAGE; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PHAGOCYTE; PHAGOCYTOSIS; RESPIRATORY CHAIN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH ULCER; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VOMITING;

GOUT; HUMANS; INFLAMMATION; TRPM CATION CHANNELS; URIC ACID;

EID: 84886938929     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2013.835399     Document Type: Review

References (31)

1. Punzi L, Scanu A, Ramonda R, et al. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev 2012;12:66-71
2. Harrold L. New developments in gout. Curr Opin Rheumatol 2013;25:304-9
3. Crittenden DB, Pillinger MH. New therapies for gout. Annu Rev Med 2013;64:325-37
4. Suresh E, Das P. Recent advances in management of gout. QJM 2012;105:407-17
5. Lottmann K, Chen X, Schadlich PK. Association between gout and all-cause as well as cardiovascular mortality: a systematic review. Curr Rheumatol Rep 2012;14:195-203
6. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109-15
7. Ramonda R, Lo Nigro A, Modesti V, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011;10:773-8
8. Jin M, Yang F, Yang I, et al. Uric acid, hyperuricemia and vascular diseases. Front Biosci 2012;17:656-69
9. Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008;CD005521
10. Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet 2011;377:165-77
11. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41
12. Gross O, Thomas CJ, Guarda G, et al. The inflammasome: an integrated view. Immunol Rev 2011;243:136-51
13. Schroder K, Tschopp J. The inflammasomes. Cell 2010;140:821-32
14. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006;126:659-62
15. Shaw PJ, McDermott MF, Kanneganti TD. Inflammasomes and autoimmunity. Trends Mol Med 2011;17:57-64
16. Strowig T, Henao-Mejia J, Elinav E, et al. Inflammasomes in health and disease. Nature 2012;481:278-86
17. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-56
18. Dostert C, Guarda G, Romero J, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009;4:e6510
19. Zhong Z, Zhai Y, Liang S, et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun 2013;4:1611
20. Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011;469:221-5
21. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012;36:401-14
22. McGuire KA, Barlan AU, Griffin TM, et al. Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species. J Virol 2011;85:10806-13
23. Kepp O, Galluzzi L, Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat Immunol 2011;12:199-200
24. Bolisetty S, Jaimes EA. Mitochondria and reactive oxygen species: physiology and pathophysiology. Int J Mol Sci 2013;14:6306-44
25. Takahashi N, Kozai D, Kobayashi R, et al. Roles of TRPM2 in oxidative stress. Cell Calcium 2011;50:279-87
26. Yamamoto S, Takahashi N, Mori Y. Chemical physiology of oxidative stress-activated TRPM2 and TRPC5 channels. Prog Biophys Mol Biol 2010;103:18-27
27. Perraud AL, Schmitz C, Scharenberg AM. TRPM2 Ca2+ permeable cation channels: from gene to biological function. Cell Calcium 2003;33:519-31
28. Fonfria E, Marshall IC, Benham CD, et al. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. Br J Pharmacol 2004;143:186-92
29. Sumoza-Toledo A, Penner R. TRPM2: a multifunctional ion channel for calcium signalling. J Physiol 2011;589:1515-25
30. Naziroglu M, Luckhoff A. A calcium influx pathway regulated separately by oxidative stress and ADP-Ribose in TRPM2 channels: single channel events. Neurochem Res 2008;33:1256-62
31. Naziroglu M. New molecular mechanisms on the activation of TRPM2 channels by oxidative stress and ADP-ribose. Neurochem Res 2007;32:1990-2001